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This paper discusses antioxidative and biological activity of 25 novel amidino substituted 
benzamides with a variety of heteroaromatic nuclei attached to the benzamide moiety and with 
a variable number of methoxy and/or hydroxy substituents. Targeted compounds, bearing either 
amidino or 2-imidazolinyl substituent, were obtained in the Pinner reaction from cyano 
precursors. 3D-QSAR models were generated to predict antioxidative activity of the 25 novel 
aromatic and heteroaromatic benzamide derivatives. The compounds were tested for 
antioxidative activity using in vitro spectrophotometric assays. Direct validation of 3D-QSAR 
approach for predicting activities of novel benzamide derivatives was carried out by comparing 
experimental and computationally predicted antioxidative activity. Experimentally determined 
activities for all novel compounds were found to be within standard deviation of error of the 
models. Following this, structure-activity relationships among the synthesized compounds are 
discussed. Furthermore, antiproliferative activity in vitro against HeLa cells as well as 
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Significant biological importance of nitrogen heterocycles, particularly benzimidazoles 
and benzothiazoles, makes them very useful building blocks in organic and medicinal 
chemistry.1,2 They are an essential structural part in numerous natural and synthetic bioactive 
compounds3 possessing a wide range of biological characteristics including antibacterial,4,5 
anticancer,6,7 antifungal,8 antiviral,9 antioxidative10,11 etc. In the last decade, particular attention 
and focus was given to their antioxidative potency. It is widely accepted that reactive oxygen 
species (ROS) could cause the oxidative damage of important biomolecules including nucleic 
acids, proteins or lipids. These reactive species could be generated in numerous 
pathophysiological and biochemical processes in the human body.12 ROS includes non-free 
radical species like ozone (O3), singlet oxygen (
1O2), hydrogen peroxide (H2O2), and free 
radicals including peroxyl radicals (ROO•), hydroperoxyl radicals (HOO•), hydroxyl radicals 
(OH•) and superoxide anion radicals (O•2). Consequently, it could lead to the development of 
some chronic diseases like cancer, diabetes, inflammation, neurodegenerative syndrome or 
aging.13,14 The proper usage of antioxidants could regulate the rate of reactive oxygen species 
production, at even at low concentration, they prevent oxidation of easily oxidizable substrate.15 
Thus, there is a constant growing interest for the study of antioxidative capacity of numerous 
natural and synthetic organic molecules with the aim of prevention of the above mentioned 
diseases.  
Recently, our scientific research focused on the antiproliferative activity of versatile 
benzimidazole and benzothiazole derivatives.16,17,18 A large number of active derivatives are 
designed to have cationic amidino substituents at the termini of the molecule, which has allowed 
additional interactions with the biological targets. Additional biological activity studies of 
tetracyclic benzimidazole derivatives have been confirmed their strong interaction with DNA 
as intercalators, while acyclic, either benzimidazole or benzothiazole, derivatives have been 
proven to be selective DNA minor groove binders.16,17,19 Recent literature data suggests that 
tumor cells are accompanied by a measurable emission of ROS which might be regulated by 
apropriate usage of antioxidant agents.20 Several publications described antioxidative activity 
and potential of benzimidazole and benzothiazole derivatives, as well as a broad range of 
salicylanilide and benzamide derivatives, as antioxidative agents.21,22,23  
In order to explore the antioxidative potency of aromatic and heteroaromatic benzamide 
derivatives bearing benzazole nuclei, we developed 3D-QSAR models and used them for 
computational prediction of antioxidative activity of the presented compounds.  
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Application of 3D-QSAR modeling for prediction of activity of novel compounds and 
identification of molecular properties with the highest influence on the studied activity was 
already proven as an useful method numerous times.24,25,26,27,28,29 In addition, antioxidative 
activity of different classes of compounds has been studied using different approaches of QSAR 
modeling.30,31,32,33 The main advantage of  Volsurf+34,35 based approach is usage of molecular 
descriptors that are independent of molecular alignment and have a clear chemical or physical 
meaning. In this paper, Volsurf+ approach for generating 3D-QSAR models was 
experimentally validated on prediction of antioxidative activity of the 25 novel compounds. 
Combining the demonstrated biological potential of benzamides and amidino substituted 
benzimidazoles and benzothiazoles, we have designed and synthesized novel derivatives 
bearing a variable number of the methoxy and hydroxy groups substituted with different 
amidino substituents. Prepared derivatives were explored for their antioxidative, antimicrobial 
and antiproliferative activity. The obtained experimental results were compared to the predicted 
results and a very good alignment was observed. 
 
2. Results and Discussion 
 
2.1. 3D-QSAR models 
 
Using a library of experimental data for antioxidative activity36,37,38 of already published 
compounds, 3D-QSAR models were built. Models with the highest predictive ability, namely 
model 1 and model 2, were chosen for the prediction of antioxidative activities of novel 
compounds. Model 1 was generated using the results obtained from the activity testing against 
DPPH stable radical while model 2 has been generated using activity from superoxide test. 
Quality of the models validated by internal cross-validation procedure, using two procedures, 
leave one out (LOO) and random groups (LMO), as well as by the external prediction (Table 
1, Figure 1). Both models show similar predictive ability (Q2LOO, Q
2
LMO, SDEPEXT in Table 1). 
Statistical properties of the models are shown in Table 1. Compounds for which activity was 
expressed only as “≥400 µM” were not included in the training set of the model 2 due to the 








Table 1. Statistical properties of 3D-QSAR models. 
Model  nO LV R2 SDEC  Q2LOO  SDEP LOO  Q2LMO SDEP LMO  SDEPEXT  nOE 
1 59 4 0.73 0.25 0.66 0.28 0.65 0.28 0.41 12 
2 32 3 0.71 0.12 0.54 0.16 0.53 0.16 0.18 7 
 
 
a Number of objects which was used to build the model (training set). b Number of latent 
variables. cSDEC - standard deviation of error of calculation. d Q2 is the cross-validated 
predictive performance, LOO stands for Leave One Out cross-validation procedure, LMO 
stands for Leave Many Out (i.e. Random Groups) cross-validation procedure. eSDEP - 
standard deviation of error of prediction obtained by cross-validation. f SDEPEXT stands for 
standard deviation of error of prediction obtained by external validation. g Number of objects 


























Figure 1. Predicted vs experimental antioxidative activity expressed as pIC50 – negative 
logarithmic value of concentration that causes 50% of antioxidative activity measured: A) 
against DPPH stable radical (model 1) and B) using superoxide test (model 2). Blue circles 
present training set compounds; red squares present test set compounds. 
 
2.1.2. 3D-QSAR analysis 
 
Principal component analysis (PCA) was performed on the overall dataset of 59 
compounds. The first two principal components explained 95% of variance (the first three PCs 
explained 98% of variance) of the descriptors (X-matrix). Molecular descriptors including 
hydrophilic (W1-W3) and hydrophobic regions (D1) related to the polarizability and dispersion 
forces, molecular volume (V), and possibility of accepting (WN1) and donating H-bonds 
(WO1) were identified, from the PCA loadings plot (Figure S63 in the Supplement), as the ones 
with the highest variation among the dataset compounds 
These results indicated to the mentioned descriptors as the ones with the highest 
variation between the dataset compounds which might be related to the variation in 
antioxidative activities of the dataset compounds. The PLS analysis could estimate the 


















pIC50 - experimental 
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The influence of each molecular descriptor to the compound’s antioxidative activity 
could be evaluated from the analyses of the PLS coefficients of the obtained 3D-QSAR. Since 
both models were generated using raw data, the real impact of a molecular descriptor on the 
antioxidative activity is given as the product of the descriptor’s value and it’s PLS coefficient.  
Such QSAR analysis performed for both models (Figure 2), enabled the finding of molecular 









Figure 2. Products of the descriptor’s average value calculated for the dataset used to derive 






























































































































































































Descriptors with the highest positive influence on antioxidative activity for both models 
have proven to be hydrophilic volume related to polarizability (W1) and possibility of a 
compound to donate H-bond (WO1). Consequently, their increase should lead to increase of 
activity measured by both tests. Possibility of a compound to accept H-bond (WN1) and sum 
of hydrophobic surface areas (HSA) are negatively correlated for both models and their 
decrease should cause the increase of antioxidatve activity in both tests.  
 
2.2.  Chemistry 
 
All chosen amide derivatives were synthesized following two synthetic procedures 
shown in Scheme 1 and 2.39 Cyano substituted benzamides 4-6 and 2-benzimidazolyl/2-
benzothiazolyl substituted benzamides 20-25 were obtained from the methoxy substituted acyl-
halogenides 1-3 and p-cyanoaniline 2 or cyano substituted 2-aminobenzimidazole 18 or 2-






In order to obtain corresponding hydroxy substituted benzamides 7-10 and 26-29 bearing cyano 
substituent, the removal of methoxy protecting groups was accomplished by using either boron 
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trichloride or boron tribromide in absolute dichloromethane at -75 °C.  Reaction yields of all 
compounds were moderate.  
By using boron trichloride, only one methoxy group has been removed from the 
compounds 5, 21 and 24 which allowed the synthesis of compounds 8, 27 and 29 with one 
methoxy and one hydroxy group. 2D NOESY NMR spectra confirmed that the methoxy group 
at the position 2 (R1) was successfully deprotected. Target compounds with variable number of 
hydroxy 11-17 and 30-37 and/or methoxy groups 38-47 bearing amidino or 2-imidazolinyl 
substituent were prepared in acidic twostep Pinner reaction from corresponding cyano 
precursors due to reaction with NH3(g) or ethylenediamine (EDA).  
 
 
 Scheme 2. 
The progress of the reaction was monitored by IR spectroscopy. In order to ensure their better 
water solubility, all amidino substituted derivatives were prepared as hydrochloride salts. Due 
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to some synthetic issues in the Pinner reaction, monomethoxy substituted analogues of amidino 
compounds 38-47 have not been successfully synthesized.    
 
2.3. Antioxidative activity 
 
Results obtained from DPPH test revealed that all tested compounds displayed improved 
or similar activity in comparison to used standard, ascorbic acid (Table 2).  
 
Table 2. Antioxidative activity of tested amidino substituted compounds. 
Compound DPPH (μM) Superoxide test (μM) 
11 59±4 137±4 
12 66±5 158±8 
13 39±3 123±4 
14 89±6 170±8 
15 70±6 156±7 
16 51±6 138±5 
17 42±5 133±7 
30 42±3 135±4 
31 38±3 130±5 
32 49±4 139±5 
33 46±7 141±6 
34 56±5 148±6 
35 65±6 163±4 
36 80±3 166±3 
37 58±3 154±5 
38 59±6 142±8 
39 52±3 145±4 
40 66±7 149±7 
41 73±4 171±7 
42 57±2 151±6 
43 71±5 163±7 
44 85±4 180±9 
45 82±4 169±5 
46 94±2 195±9 
47 73±4 172±8 
Ascorbic acid 79±3 95±2 
Interestingly, a regularly behavior was noticed in the pairs of tested bioisosteric compounds. 
The radical scavenging test for the compounds with amidino moiety always resulted in ehanced 
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activity when compared to compound having imidazole moiety in the same position (pairs are 
as goes: 11 and 14, 30 and 34, 32 and 36, 40 and 45, 12 and 15, 31 and 35, 33 and 37, 38 and 
43, 41 and 46, 13 and 16, 39 and 44, 42 and 47).  
According to the presented results, the compound with the highest antioxidative 
potential has proven to be 13, with the activity almost 50% better in comparison to the control 
compound (ascorbic acid). The pair of compounds including 13 and 16, is the only one having 
two hydroxy groups in positions 2 and 4, and thus has a highest potential for radical transfer to 
stable DPPH radical and still maintain his stability by resonance stabilization. Compared to 
compound 13, its bioisosteric compounds 11, having hydroxy group on first phenyl ring in 
position 2, and compound 12, with hydroxy and methoxy groups placed in positions 2 and 4 
respectively, showed significantly lower activity, although still better than control compound. 
From this result we can conclude that hydroxy groups are important for activity in order to 
promote radical scavenging activity. This is in accordance with QSAR analysis showing that 
the values of descriptors WO1 and W1 are higher for compounds 11-13 comparing to ascorbic 
acid, while the opposite is true for the descriptors WN1 and HSA (Figure 3).   
In second performed antioxidative test, which included measuring capability of compounds for 
superoxide anion radical scavenging, all compounds showed lower activity compared to 
ascorbic acid. Nevertheless, compound 13 is the most active in this test as well.  
 
Figure 3. Comparison of values of the descriptors with the highest influence on activity for the 
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2.4. Comparison of predicted and experimental antioxidative activities 
 
Internal validation using cross validation procedure, as well as validation by external 






































Figure 4. Comparison of experimental (orange squares) and computationally predicted (blue 
circles) antioxidative activities of the synthetized compounds expressed as IC50. Error bars 
coloured blue on the blue circles present standard deviation of error of prediction (SDEP) of 
the 3D-QSAR model used to predict activities: A) model 1 and B) model 2, while orange error 
bars on orange squares present standard deviation of experimental measurements.  
However, the experimental measurements of the activities of novel compounds whose activities 
were previously predicted by the QSAR model should be the most direct and reliable method 
for validation of prediction ability of built QSAR model. The antioxidative activities of 25 novel 
compounds (11-17 and 30-47), were predicted by using model 1 and model 2. Therefore, 
experimental measurements of their antioxidative activity enabled direct validation of the 
obtained 3D-QSAR models (Table 3 and Figure 4). Antioxidative activities of all 25 newly 
synthesised compounds are correctly predicted by both models i.e. experimentally measured 
activities for all novel compounds are within standard deviation of error of prediction (SDEP) 
of the models estimated by cross-validation procedure (Figure 3). Correlation coefficients (R2) 
between experimental and predicted values of antioxidative activities were 0.82 and 0.78 for 
the models 1 and 2, respectively. Furthermore, comparison of experimental and predicted 
activities shows that for majority of the novel compounds (18 out of 25) predicted antioxidative 
activity is within experimental error (Figure 4). For 7 compounds for which discrepancy of 
predicted and experimental activity is larger than standard deviation of experimental 
measurements, predicted values are smaller than experimental, showing that models slightly 
underestimated antioxidative activity of these compounds.  
 
2.4. Antiproliferative, antibacterial and antifungal activity  
 
Additionally, to explore and confirm the biological potential of newly prepared 
compounds, antiproliferative activity in vitro, antibacterial and antifungal activities were 
evaluated. As the antiproliferative potency of suchlike compounds was previously confirmed 
in our published papers, the synthesized compounds were tested against HeLa cancer cells. 
Obtained results are depicted in the Table 3 while cisplatin was used as a standard anticancer 
drug. Obtained results indicated that the majority of tested compounds showed moderate to low 
activity at micromolar inhibition concentrations.  
In general, it could be concluded that benzothiazole derivatives showed stronger 
antiproliferative activity in comparison to their benzimidazole analogues with the exception of 
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2,4-dimethoxy substituted benzimidazole 43 bearing 2-imidazolinyl group. Thus, the strongest 
antiproliferative activity against HeLa cells displayed 2-hydroxy 36 (IC50 = 23.0 μM) and 2,4-
dimethoxy 45 (IC50 = 13.6 μM) substituted benzothiazoles bearing 2-imidazolinyl group and 
2-methoxy 40 (IC50 = 20.1 μM) and 3,4,5-trimethoxy 42 (IC50 = 32.8 μM) substituted 
benzothiazoles bearing amidino substituent. All tested amidino substituted benzamides 11-17 
showed very low antiproliferative activity.  
 
Table 3. Antiproliferative activity in vitro against HeLa cells. 
Comp. IC50 (µM) 





























Furthermore, the in vitro antibacterial activity of the prepared compounds was evaluated against 
eight different bacterial strains fully sensitive to antibiotics. Gram-positive bacterial strains 
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included key representatives of human pathogens including S. aureus, M. luteus, B. subtilis and 
C. sporogenes, while the panel of Gram-negative bacteria included E. coli, P. hauseri, P. 
aeruginosa and K. pneumonia. Obtained results were displayed in Table 4 as the minimal 
inhibitory concentrations (MICs) and are compared to antibiotic amikacin used as a standard. 
In Table 4 are shown only results for compounds which showed some activity. 
 


















11 4.23 2.14 2.14 2.14 4.23 2.14 0.13 0.27 
13 2.03 2.03 2.03 4.06 4.06 2.03 1.02 2.03 
17 0.89 0.89 1.77 0.89 1.77 1.77 0.89 0.89 
31 3.46 3.46 3.46 3.46 6.91 6.91 3.46 3.46 
32 7.17 7.17 7.17 7.17 7.17 7.17 7.17 7.17 
34 6.99 3.50 6.99 6.99 6.99 6.99 6.99 3.50 
39 0.37 0.37 0.77 0.77 0.77 0.77 0.37 1.54 
43 3.11 6.22 6.22 6.22 6.22 3.11 1.56 0.78 
47 1.39 1.39 0.70 1.39 1.39 1.39 0.70 1.39 
Amikacin 0.012 0.085 0.009 0.003 0.014 0.019 0.072 0.026 
 
 
The obtained results revealed that the compound with the most significant antibacterial 
activity proved to be 3,4,5-trimethoxy substituted benzimidazole derivative 39 bearing amidino 
group (MICs value 0.37-1.54 µg/mL) without conspicuous selectivity between Gram-negative 
and Gram-positive bacteria. The highest activity was observed against P. hauseri, P. aeruginosa 
and B. subtilus bacteria with MIC value 0.37 µg/mL. 3,4,5-trihydroxy substituted benzamide 
derivative 17 bearing 2-imidazolinyl group showed also promising antibacterial activity with 
MICs values 0.89-1.77 µg/mL. Interestingly, compounds 36, 40, 42 and 45 which showed the 
most pronounced antiproliferative activity were not active on tested bacterial strains at all. In 
addition, the antifungal activity of prepared compounds was also tested against tree strains 
including C. albicans, A. brasiliensis and S. cerevisiae. The obtained results for compounds 
which displayed some activity are presented in Table 5 including the nystatin which was used 




Table 5. Antifungal activity of tested compounds. 
Comp. 
MIC (mM) 
C. albicans A. brasiliensis S. cerevisiae 
11 0.54 1.07 0.54 
12 0.25 1.94 0.25 
13 0.26 8.12 0.51 
15 0.90 1.80 0.45 
16 0.12 0.94 0.12 
17 0.19 0.94 0.19 
31 0.22 1.73 0.11 
32 0.90 1.79 1.79 
33 0.82 3.30 0.41 
34 0.11 1.75 0.11 
38 0.21 0.83 0.11 
39 0.19 1.54 0.39 
40 0.11 3.45 0.43 
43 0.20 0.78 0.20 
44 0.18 1.44 0.18 
45 0.20 3.21 0.10 
47 0.69 1.34 0.35 
Nystatin 2.70 1.35 1.35 
     
In general, obtained results revealed that some tested compounds showed better and 
improved antifungal activity in comparison to antibacterial activity. The most pronounced and 
significantly improved antifungal activity of tested compounds was observed against C. 
albicans as well as against S. cerevisiae strains compared to the standard drug nystatin. Only 
2-hydroxy substituted benzothiazole derivative bearing amidino group 32 showed weaker 
antifungal activity against S. cerevisiae in comparison to nystatin. The most active compounds 
with high antifungal potential have proven to be 2-hydroxy substituted benzimidazole 34 and 
2,4-dihydroxy substituted benzamide 16 both bearing 2-imidazolinyl group with MICs values 
0.11 and 0.12 µg/mL. Also, among all compounds showing antifungal activity, benzimidazole 
derivatives displayed more pronounced antifungal activity in comparison to their benzothiazole 
analogues. In conclusion, it is obvious that this type of amidino substituted benzimidazole and 
benzothiazole derivatives have a high potential for further optimization and design of very 







Within this paper, we present the design and synthesis of 25 novel amidino substituted 
benzamides that differ in the heteroaromatic nuclei attached to the benzamide moiety as well 
as in the number of methoxy and hydroxy groups. All synthesized benzamide derivatives, were 
also, besides with methoxy and hydroxy groups, substituted with either amidino or 2-
imidazolinyl group and are prepared within the acidic Pinner reaction from corresponding 
cyano substituted precursors. In order to ensure better solubility, all amidino derivatives were 
prepared as their hydrochloride salts.  
For prediction of the antioxidative activities of 25 novel compounds, 3D-QSAR models 
were generated and validated. Comparison of computationally predicted and experimentally 
obtained activities indicated that 3D-QSAR method can be successfully applied for design of 
novel methoxy and hydroxy substituted heteroaromatic amides as well as to successfully predict 
their antioxidative potential. 
The experimental evaluation of antioxidative activity revealed that hydroxy groups are 
essential and promote radical scavenging activity. The most pronounced antioxidative activity 
was observed for the compound 13. DPPH test showed that all novel compounds showed 
improved or similar antioxidative activity compared to standard, ascorbic acid. Furthermore, 
the majority of tested compounds displayed moderate to low antiproliferative activity at 
micromolar inhibitory concentrations. In general, it could be concluded that benzothiazole 
derivatives showed stronger antiproliferative activity in comparison to their benzimidazole 
analogues. The strongest antiproliferative activity against HeLa cancer cells showed the 
compound 45. Additionally, to confirm the great biological potential of suchlike derivatives, 
the antibacterial and antifungal activities were evaluated. The compound with the most 
significant in vitro antibacterial activity proved to be 3,4,5-trimethoxy substituted 
benzimidazole derivative 39. Antifungal activity of the tested compounds was significantly 
better than their antibacterial activity, while the majority of tested compounds showed improved 
activity in comparison to standard.  
 To conclude, all presented results of biological activities evaluation, confirmed the high 
biological potential of amidino substituted benzimidazole and benzothiazole derivatives, with 
several compounds which could be chosen as lead compounds for a further structure 
modification and optimization of suchlike scaffold in order to developed more efficient 
biologically active molecules with enhanced antioxidant potential.   
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4. Experimental part 
4.1. 3D-QSAR modelling 
4.1.1. Dataset 
3D-QSAR models were generated using the data on antioxidative activities of methoxy 
and hydroxy substituted heteroaromatic amides found in the literature.41,42 For each compound, 
antioxidative activities were measured using two tests, DPPH stable radical and superoxide 
tests, and expressed as IC50 values i.e. concentration that causes 50% antioxidative activity. For 
purpose of generating 3D-QSAR models, pIC50 (negative logarithm of IC50 value expressed in 
mol dm-3) were calculated. Dataset for model 1, generated using activities against DPPH stable 
radical, consisted of 59 compounds from the literature, while dataset for model 2, generated 
using activities obtained with superoxide test, consisted of 32 compounds from the literature.  
4.1.2. Molecular descriptors 
Molecular descriptors for each compound were generated with program Volsurf+.33,34 
Starting from the SMILES codes, 3D structures were generated using VolSurf+ 3D structure 
generator. Considering high rigidity of the dataset compounds, VolSurf+ 3D structure generator 
was considered to be powerful enough to produce the most relevant conformers and no 
additional conformational search was applied. Using following probes: H2O (the water 
molecule), O (sp2 carbonyl oxygen atom), N1 (neutral NH group (e.g. amide)), and DRY (the 
hydrophobic probe), Molecular Interaction Fields (MIFs) were calculated. From the MIFs, 128 
descriptors with clear chemical and physical meaning were calculated for each compound. The 
detailed description of all 128 VolSurf+ descriptors is given in the VolSurf+ manual.35,36 
4.1.3. Partial Least Square and Principal Component analysis 
Partial Least Square (PLS) analysis was applied with goal of finding the relationship 
between the 3D structure-based molecular descriptors and antioxidative activities. The number 
of significant latent variables (nLV) and quality of the models were determined using the leave-
one-out (LOO) cross-validation procedures and leave many out (LMO) cross-validation 
procedure with eight random groups. Also, for each model, standard deviation of error of 
calculation (SDEC) and standard deviation of error of prediction (SDEP) were calculated. 
Validation of predictive ability of each model was also performed using external validation. 
For that purpose, dataset was divided into the training set, that was used to build the model, and 
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the test set, that was used to validate predictive ability of the model. Standard deviation of error 
of prediction (SDEP) for external prediction was calculated for each model.   
In order to identify molecular descriptors with the highest positive or negative impact 
on antioxidative activities of studied compounds, analyses of PLS coefficients of the 3D-QSAR 
models were performed. Models were built using raw data (without autoscaling pretreatment 
of descriptors) and the quantitative influence of each descriptor on the anti-proliferative activity 
is given as product of the descriptor’s value and it’s PLS coefficient.  
Principal Component Analysis (PCA) was performed on the molecular descriptors of 
the complete dataset (all 59 compounds). PCA loadings were used for identification of the 
descriptors with the highest contribution to the overall variance in the X-space.  
 
4.2. Synthesis 
4.2.1. General Methods 
All chemicals and solvents were purchased from commercial available suppliers 
including Aldrich, Fluka and Acros. Melting points were recorded on an Original Keller 
Mikroheitztisch apparatus (Reichert, Wien), SMP11 Bibby and Büchi 535 apparatus and are 
not corrected. 1H and 13C NMR spectra were recorded on a Varian Gemini 300 or Varian Gemini 
600 spectrophotometers at 300, 600, 150 and 75 MHz, respectively. All NMR spectra were 
measured in DMSO-d6 solutions using TMS as an internal standard. Chemical shifts are 
reported in ppm (δ) relative to TMS. All compounds were routinely checked by thin layer 
chromatography (TLC) using precoated Merck silica gel 60F-254 plates and the spots were 
detected under UV light (254 nm). Column chromatography (CC) was performed using silica 
gel (0.063–0.2 mm) Fluka; glass column was slurry-packed under gravity. 
 
4.2.2. General method for the preparation of carboxamides 20-25 
To a solution of mono-, di- or tri-methoxy substituted benzoyl-chloride in dry toluene 
corresponding amine was added followed by the addition of Et3N. The reaction mixture was 
refluxed for 24 hours. After cooling the resulting product was filtered off and washed with 
diluted HCl and water to obtain pure solid. 
 
2-Methoxy-N-[5(6)-cyano-1H-benzimidazol-2-yl]benzamide 20     
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Following the general method, from 0.32 g (1.9 mmol) 2-methoxybenzoylchloride 1, 0.30 g 
(1.9 mmol) 2-amino-5(6)-cyano-1H-benzimidazole 18 and 0.27 g (2.7 mmol) Et3N in dry 
toluene (15 ml), 0.47 g (86%) of white powder was obtained; mp 234–237 °C; 1H NMR (300 
MHz, DMSO-d6) (δ/ppm): 11.55 (s, 1H, NHamide), 7.92 (s, 1H, Harom), 7.79 (dd, J1 = 7.6 Hz, J2 
= 1.6 Hz, 1H, Harom), 7.63 (t, J = 7.2 Hz, 2H, Harom), 7.55 (t, J = 8.2 Hz, 1H, Harom), 7.25 (d, J 
= 8.4 Hz, 1H, Harom), 7.13 (t, J = 7.5 Hz, 1H, Harom), 3.96 (s, 3H, CH3);
 13C NMR (150 MHz, 
DMSO-d6) (δ/ppm): 165.1, 157.1, 148.6, 133.6, 130.2, 125.1, 121.9, 120.7 (2C), 120.2, 112.3 
(2C), 56.2. 
2-Methoxy-N-(6-cyanobenzothiazol-2-yl)benzamide 23      
Following the general method, from 0.29 g (1.7 mmol) 2-methoxybenzoylchloride 1, 0.30 g 
(1.7 mmol) 2-amino-6-cyanobenzothiazole 19 and 0.24 g (2.4 mmol) Et3N in dry toluene (15 
ml), 0.40 g (77%) of white powder was obtained; mp 238–241 °C; 1H NMR (300 MHz, DMSO-
d6) (δ/ppm): 12.40 (s, 1H, NHamide), 8.62 (d, J = 1.1 Hz, 1H, Harom), 7.92 (d, J = 8.4 Hz, 1H, 
Harom), 7.86 (dd, J1 = 8.4 Hz, J2 = 1.6 Hz, 1H, Harom), 7.75 (dd, J1 = 7.7, J2 = 1.7 Hz, 1H, Harom), 
7.62 (t, J = 7.0 Hz, 1H, Harom), 7.25 (d, J = 8.3 Hz, 1H, Harom), 7.13 (t, J = 7.5 Hz, 1H, Harom), 
3.95 (s, 3H); 13C NMR (75 MHz, DMSO-d6) (δ/ppm): 165.9, 162.1, 157.8, 152.2, 134.4, 132.8, 
130.8, 130.1, 127.6, 121.7, 121.2, 119.6, 112.8, 105.9, 56.6. 
2,4-Dimethoxy-N-(6-cyanobenzothiazol-2-yl)benzamide 24    
Following the general method, from 1.94 g (9.7 mmol) 2,4-dimethoxybenzoylchloride 2, 1.7 g 
(9.7 mmol) 2-amino-6-cyanobenzothiazole 19 and 1.37 g (13.6 mmol) Et3N in dry toluene (30 
ml), 2.58 g (78%) of white powder was obtained; mp > 280 °C; 1H NMR (300 MHz, DMSO-
d6) (δ/ppm): 11.89 (s, 1H, NHamide), 8.60 (d, J = 1.0 Hz, 1H, Harom), 7.93 – 7.82 (m, 3H, Harom), 
6.78 – 6.70 (m, 2H, Harom), 4.00 (s, 3H, CH3), 3.88 (s, 3H, CH3); 
13C NMR (150 MHz, DMSO-
d6) (δ/ppm): 164.5, 164.1, 161.6, 159.4, 151.7, 132.7, 132.4, 129.6, 127.0, 121.1, 119.2, 112.5, 
106.5, 105.3, 98.7, 56.5, 55.8. 
3,4,5-Trimethoxy-N-(6-cyanobenzothiazol-2-yl)benzamide 25      
Following the general method, from 2.95 g (13.0 mmol) 3,4,5-trimethoxybenzoylchloride 3, 
2.24 g (13.0 mmol) 2-amino-6-cyanobenzothiazole 19 and 1.88 g (13.0 mmol) Et3N in dry 
toluene (30 ml), 3.30 g (69%) of white powder was obtained; mp 251–253 °C; 1H NMR (600 
MHz, DMSO-d6) (δ/ppm): 13.16 (brs, 1H, NHamide), 8.62 (s, 1H, Harom), 7.92 (d, J = 8.3 Hz, 
1H, Harom), 7.87 (dd, J1 = 8.4 Hz, J2 = 1.5 Hz, 1H, Harom), 7.54 (s, 2H, Harom), 3.90 (s, 6H, 
OCH3), 3.77 (s, 3H, OCH3); 
13C NMR (75 MHz, DMSO-d6) (δ/ppm): 165.7, 163.3, 153.3 (2C), 
142.0, 130.2, 127.6, 126.5, 121.6, 119.7, 106.5 (2C), 105.9, 60.6, 56.6 (2C). 
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4.2.3. General method for the preparation of hydroxy substituted compounds 7-10 and 
26-29 
Corresponding methoxy substituted compound was dissolved in dry dichloromethane, 
cooled to -78 °C and BCl3 or BBr3 was added under argon atmosphere. The reaction mixture 
was stirred on that temperature for several hours and kept refrigerated overnight. The reaction 
was quenched by the addition of methanol, solvent was evaporated to dryness and the residue 
was purified by column chromatography (CH2Cl2/CH3OH). 
 
2-Hydroxy-N-(4-cyanophenyl)benzamide 7  
Following the general method, from 0.37 g (1.5 mmol) 2-methoxy-N-(4-
cyanophenyl)benzamide 4 and 5.0 ml BCl3 (2.2 mmol) in absolute dichloromethane (20 ml) 
under the argon to obtain 0.31 g (85%) of white powder; mp 177–180 °C; 1H NMR (300 MHz, 
DMSO-d6) (δ/ppm): 11.38 (brs, 1H, OH), 10.65 (s, 1H, NHamide), 7.94 (d, J = 8.8 Hz, 2H, Harom), 
7.88 (dd, J1 = 7.9 Hz, J2 = 1.6 Hz, 1H, Harom), 7.83 (d, J = 8.8 Hz, 2H, Harom), 7.45 (m, 1H, 
Harom), 7.02 – 6.95 (m, 2H, Harom); 
13C NMR (150 MHz, DMSO-d6) (δ/ppm): 166.5, 157.5, 
142.7, 133.7, 133.2 (2C), 129.5, 120.4 (2C), 119.2, 119.0, 118.5, 117.1, 105.6. 
2-Hydroxy-4-methoxy-N-(4-cyanophenyl)benzamide 8  
Following the general method, from 0.50 g (1.8 mmol) 2,4-dimethoxy-N-(4-
cyanophenyl)benzamide 5 and 10.0 ml BCl3 (5.3 mmol) in absolute dichloromethane (30 ml) 
under the argon to obtain 0.21 g (44%) of beige powder; mp 222–225 °C; 1H NMR (600 MHz, 
DMSO-d6) (δ/ppm): 11.99 (brs, 1H, OH), 10.50 (s, 1H, NHamide), 7.95 (d, J = 8.0 Hz, 1H, Harom), 
7.92 (d, J = 9.1 Hz, 1H, Harom), 7.82 (d, J = 8.8 Hz, 1H, Harom), 6.58 (dd, J1 = 8.9 Hz, J2 = 2.4 
Hz, 1H, Harom), 6.52 (d, J = 2.4 Hz, 1H, Harom), 3.80 (s, 3H, OCH3); 
13C NMR (150 MHz, 
DMSO-d6) (δ/ppm): 167.0, 164.0, 161.0, 142.7, 133.1 (2C), 130.7, 120.7 (2C), 119.0, 109.5, 
106.5, 105.5, 101.3, 55.5. 
2,4-Dihydroxy-N-(4-cyanophenyl)benzamide 9  
Following the general method, from 0.50 g (1.8 mmol) 2,4-dimethoxy-N-(4-
cyanophenyl)benzamide 5 and 10.0 ml BBr3 (2.7 mmol) in absolute dichloromethane (30 ml) 
under the argon to obtain 0.06 g (13%) of beige powder; mp 250–253 °C; 1H NMR (300 MHz, 
DMSO-d6) (δ/ppm): 11.87 (brs, 1H, OH), 10.44 (s, 1H, NHamide), 10.26 (brs, 1H, OH), 7.91 (d, 
J = 8.8 Hz, 2H, Harom), 7.87 (d, J = 8.7 Hz, 1H, Harom), 7.81 (d, J = 8.7 Hz, 2H, Harom), 6.41 (dd, 
J1 = 8.6 Hz, J2 = 2.3 Hz, 1H, Harom), 6.38 (d, J = 2.3 Hz, 1H, Harom); 
13C NMR (75 MHz, DMSO-




3,4,5-Trihydroxy-N-(4-cyanophenyl)benzamide 10      
Following the general method, from 0.50 g (1.6 mmol) 3,4,5-trimethoxy-N-(4-
cyanophenyl)benzamide 6 and 15.0 ml BBr3 (15.0 mmol) in absolute dichloromethane (30 ml) 
under the argon to obtain 0.31 g (71%) of white powder; mp 273–275 °C; 1H NMR (300 MHz, 
DMSO-d6) (δ/ppm): 10.30 (s, 1H, NHamide), 9.22 (s, 2H, OH), 8.91 (s, 1H, OH), 7.97 (d, J = 8.8 
Hz, 2H, Harom), 7.78 (d, J = 8.7 Hz, 2H, Harom), 6.97 (s, 2H, Harom); 
13C NMR (75 MHz, DMSO-
d6) (δ/ppm): 166.6, 146.0, 144.4, 137.8, 133.5 (2C), 124.7, 120.4 (2C), 119.7, 107.9 (2C), 105.2. 
2-Hydroxy-N-[5(6)-cyano-1H-benzimidazol-2-yl]benzamide 26     
Following the general method, from 0.50 g (1.7 mmol) 2-methoxy-N-[5(6)-cyano-1H-
benzimidazol-2-yl]benzamide 20 and 10.0 ml BBr3 (10.0 mmol) in absolute dichloromethane 
(25 ml) under the argon to obtain 0.35 g (74%) of white powder; mp > 280 °C;  1H NMR (300 
MHz, DMSO-d6) (δ/ppm):
 12.91 (brs, 2H, NHbenzimidazole, OH), 8.02 (dd, J1 = 7.7 Hz, J2 = 1.3 
Hz, 1H, Harom), 7.90 (s, 1H, Harom), 7.69 – 7.57 (m, 2H, Harom), 7.44 (t, J = 7.0 Hz, 1H, Harom), 
6.94 (m, 2H, Harom);
 13C NMR (75 MHz, DMSO-d6) (δ/ppm): 200.7, 173.8, 165.9, 164.3, 150.2, 
124.2, 116.1, 108.9. 
2-Hydroxy-4-methoxy-N-[5(6)-cyano-1H-benzimidazol-2-yl]benzamide 27    
Following the general method, from 0.20 g (0.6 mmol) 2,4-dimethoxy-N-[5(6)-cyano-1H-
benzimidazol-2-yl]benzamide 21 and 3.6 ml BBr3 (3.6 mmol) in absolute dichloromethane (15 
ml) under the argon to obtain 0.14 g (59%) of white powder; mp > 280 °C; 1H NMR (300 MHz, 
DMSO-d6) (δ/ppm): 12.05 (brs, 2H, NHbenzimidazole, NHamide), 8.58 (s, 1H, Harom), 8.01 (d, J = 
8.9 Hz, 1H, Harom), 7.86 (s, 2H, Harom), 6.63 (dd, J1 = 8.9 Hz, J2 = 2.4 Hz, 1H, Harom), 6.58 (d, J 
= 2.3 Hz, 1H, Harom), 6.47 (s, 1H, Harom), 3.82 (s, 3H, CH3); 
13C NMR (150 MHz, DMSO-d6) 
(δ/ppm): 167.6, 164.2, 131.7 (2C), 129.6, 126.5, 119.6 (2C), 106.5, 104.1, 101.0 (2C), 55.4. 
2-Hydroxy-N-(6-cyanobenzothiazol-2-yl)benzamide 28        
Following the general method, from 0.50 g (1.6 mmol) 2-methoxy-N-[5(6)-cyano-1H-
benzothiazol-2-yl]benzamide 23 and 10.0 ml BBr3 (10.0 mmol) in absolute dichloromethane 
(25 ml) under the argon to obtain 0.37 g (78%) of white powder; mp > 280 °C; 1H NMR (300 
MHz, DMSO-d6) (δ/ppm): 12.30 (brs, 1H, NHamide), 11.77 (brs, 1H, OH), 8.61 (s, 1H, Harom), 
7.99 (dd, J1 = 7.9 Hz, J2 = 1.6 Hz, 1H, Harom), 7.93 – 7.84 (m, 2H, Harom), 7.53 (t, J = 7.7 Hz, 
1H, Harom), 7.13 – 6.99 (m, 2H, Harom); 
13C NMR (150 MHz, DMSO-d6) (δ/ppm): 144.0, 134.9, 
130.6, 129.8, 127.2, 119.9, 119.1, 117.6, 117.2, 105.5. 
 
2-Hydroxy-4-methoxy-N-(6-cyanobenzothiazol-2-yl)benzamide 29   
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Following the general method, from 0.50 g (1.5 mmol) 2,4-dimethoxy-N-(6-
cyanobenzothiazol-2-yl)benzamide 24 and 0.65 g (5.6 mmol) BCl3 in dichloromethane (30 ml) 
under the argon to obtain 0.12 g (25%) of yellow powder; mp > 280 °C; 1H NMR (300 MHz, 
DMSO-d6) (δ/ppm): 12.21 (brs, 2H, OH, NHamide), 8.60 (s, 1H, Harom), 8.03 (d, J = 8.8 Hz, 1H, 
Harom), 7.88 (s, 2H), 6.65 (dd, J1 = 8.9 Hz, J2 = 2.2 Hz, 1H, Harom), 6.59 (d, J = 2.1 Hz, 1H, 
Harom), 3.84 (s, 3H); 
13C NMR (75 MHz, DMSO-d6) (δ/ppm): 165.2, 132.7, 130.3, 127.6, 119.6, 
107.7, 105.9, 101.8, 56.0. 
 
4.2.4. General method for the preparation of amidines  
Dry HCl gas was bubbled for 4 h into a cooled suspension (0 °C) of nitrile compound 
in anhydrous ethanol or methoxyethanol. The suspension was stirred at room temperature until 
the –CN band was undetectable (IR). After anhydrous diethylether was added, the 
corresponding imidate ester was filtered off and dried in vacuo. The product was then 
suspended in anhydrous ethanol and the corresponding amine was added. For the synthesis of 
unsubstituted amidines, the suspension was treated with anhydrous ammonia gas and stirred for 
24 h at room temperature. For the synthesis of imidazolinyl-substituted amidines, excess of 
ethylenediamine (3.5 molar equivalents) was added to a suspension of imidate ester and the 
reaction mixture was stirred at reflux for 24 h. The crude product was then filtered off and 
washed with diethylether to give powder products which were suspended in anhydrous ethanol 
and saturated with HCl gas. The reaction mixture was stirred at room temperature for 24 h. The 
products were filtered off. 
2-Hydroxy-N-(4-amidinophenyl)benzamide 11    
The compound was prepared following the general method. A suspension of 0.19 g (0.8 mmol) 
2-hydroxy-N-(4-cyanophenyl)benzamide 7 in anhydrous ethanol (15 ml) was saturated with dry 
HCl gas and stirred for 5 days. The crude imidate was filtered off, suspended in absolute ethanol 
(8 ml) and dry NH3 was bubbled into the suspension. The mixture was worked up as it is 
described to give 0.98 g (87%) of light yellow powder; mp 270–273 °C; 1H NMR (300 MHz, 
DMSO-d6) (δ/ppm): 15.69 (brs, 1H, NHamide), 8.92 (brs, 4H, NHamidine), 7.84 (s, 4H, Harom), 7.2 
(dd, J1 = 7.8 Hz, J2 = 1.8 Hz, 1H, Harom), 7.07 – 7.01 (m, 1H, Harom), 6.49 (d, J = 8.2 Hz, 1H, 
Harom), 6.27 (t, J = 7.3 Hz, 1H, Harom), 4.35 (brs, 1H, OH); 
13C NMR (150 MHz, DMSO-d6) 
(δ/ppm): 169.9, 167.3, 164.8, 145.8, 132.6, 129.6, 129.2 (2C), 121.0, 120.9, 120.3, 118.9 (2C), 
118.0, 111.2. 
2-Hydroxy-4-methoxy-N-(4-amidinophenyl)benzamide 12    
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The compound was prepared following the general method. A suspension of 0.12 g (0.4 mmol) 
2-hydroxy-4-methoxy-N-(4-cyanophenyl)benzamide 8 in anhydrous ethanol (10 ml) was 
saturated with dry HCl gas and stirred for 4 days. The crude imidate was filtered off, suspended 
in absolute ethanol (10 ml) and dry NH3 was bubbled into the suspension. The mixture was 
worked up as it is described to give 0.07 g (51%) of light rose powder; mp 256–259 °C; 1H 
NMR (600 MHz, DMSO-d6) (δ/ppm): 15.47 (brs, 1H, NHamide), 9.13 (brs, 4H, NHamidine), 7.84 
(d, J = 8.8 Hz, 2H, Harom), 7.81 (d, J = 8.8 Hz, 2H, Harom), 7.61 (d, J = 8.7 Hz, 1H, Harom), 5.94 
(d, J = 2.1 Hz, 1H, Harom), 5.87 (dd, J1 = 8.7 Hz, J2 = 2.3 Hz, 1H, Harom), 4.36 (brs, 1H, OH), 
3.67 (s, 3H, OCH3); 
13C NMR (150 MHz, DMSO-d6) (δ/ppm): 172.8, 167.3, 164.9, 163.6, 
146.6, 130.5, 129.2 (2C), 119.4, 118.6 (2C), 111.9, 103.5, 99.3, 54.4. 
2,4-Dihydroxy-N-(4-amidinophenyl)benzamide 13     
The compound was prepared following the general method. A suspension of 0.30 g (1.2 mmol) 
2,4-dihydroxy-N-(4-cyanophenyl)benzamide 9 in anhydrous ethanol (15 ml) was saturated with 
dry HCl gas and stirred for 9 days. The crude imidate was filtered off, suspended in absolute 
ethanol (15 ml) and dry NH3 was bubbled into the suspension. The mixture was worked up as 
it is described to give 0.06 g (17%) of light brown powder; mp > 280 °C; 1H NMR (600 MHz, 
DMSO-d6) (δ/ppm): 15.67 (brs, 1H, NHamide), 8.94 (brs, 6H, NHamidine, OH), 7.82 – 7.78 (m, 
4H, Harom), 7.53 (d, J = 8.6 Hz, 1H, Harom), 5.82 (s, 1H, Harom), 5.78 (d, J = 8.5 Hz, 1H, Harom);
 
13C NMR (150 MHz, DMSO-d6) (δ/ppm): 172.8, 167.7, 165.2, 162.4, 146.9, 131.2, 129.7 (2C), 
120.0, 119.0 (2C), 111.5, 105.8, 101.6. 
2-Hydroxy-N-[4-(imidazolin-2-yl)phenyl]benzamide 14    
The compound was prepared following the general method. A suspension of 0.19 g (0.8 mmol) 
2-hydroxy-N-(4-cyanophenyl)benzamide 7 in anhydrous ethanol (15 ml) was saturated with dry 
HCl gas and stirred for 5 days. The crude imidate was filtered off and suspended in absolute 
ethanol. EDA (0.09 ml, 1.4 mmol) was added and the mixture was stirred at reflux for 24 h. 
The mixture was worked up as it is described to give 0.09 g (37%) of beige powder; mp 290–
293 °C; 1H NMR (300 MHz, DMSO-d6) (δ/ppm): 11.52 (brs, 1H, NHamide), 10.79 (s, 1H, OH), 
10.64 (brs, 2H, NHamidine), 8.07 (d, J = 8.8 Hz, 2H, Harom), 8.01 (d, J = 8.7 Hz, 2H, Harom), 7.93 
(d, J = 7.7 Hz, 1H, Harom) 7.45 (t, J = 7.6 Hz, 1H, Harom), 7.07 (d, J = 8.2 Hz, 1H, Harom), 6.98 
(t, J = 7.5 Hz, 1H, Harom), 3.99 (s, 4H, CH2); 
13C NMR (75 MHz, DMSO-d6) (δ/ppm): 166.4, 
164.1, 157.5, 144.0, 133.7, 129.8 (2C), 129.7, 120.0 (2C), 119.2, 118.5, 117.1, 116.7, 44.2 (2C). 
 
2-Hydroxy-4-methoxy-N-[4-(imidazolin-2-yl)phenyl]benzamide 15    
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The compound was prepared following the general method. A suspension of 0.20 g (0.8 mmol) 
2-hydroxy-4-methoxy-N-(4-cyanophenyl)benzamide 8 in anhydrous ethanol (35 ml) was 
saturated with dry HCl gas and stirred for 4 days. The crude imidate was filtered off and 
suspended in absolute ethanol. EDA (0.07 ml, 1.1 mmol) was added and the mixture was stirred 
at reflux for 24 h. The mixture was worked up as it is described to give 0.06 g (24%) of white 
powder; mp 292–295 °C; 1H NMR (600 MHz, DMSO-d6) (δ/ppm): 12.13 (s, 1H, NHamide), 
10.72 (s, 3H, NHamidine, OH), 8.09 (d, J = 8.7 Hz, 2H, Harom), 8.06 (d, J = 8.8 Hz, 1H, Harom), 
8.01 (d, J = 8.7 Hz, 2H, Harom), 6.61 (d, J = 1.9 Hz, 1H, Harom), 6.58 (dd, J1 = 8.9 Hz, J2 = 1.9 
Hz, 1H, Harom), 3.99 (s, 4H, CH2), 3.81 (s, 3H, OCH3); 
13C NMR (75 MHz, DMSO-d6) (δ/ppm): 
167.4, 164.5, 164.4, 161.3, 144.5, 131.5, 130.2 (2C), 120.7 (2C), 117.1, 110.1, 106.9, 101.8, 
55.9, 44.7 (2C). 
2,4-Dihydroxy-N-[4-(imidazolin-2-yl)phenyl]benzamide 16     
The compound was prepared following the general method. A suspension of 0.14 g (0.6 mmol) 
2,4-dihydroxy-N-(4-cyanophenyl)benzamide 9 in anhydrous ethanol (10 ml) was saturated with 
dry HCl gas and stirred for 10 days. The crude imidate was filtered off and suspended in 
absolute ethanol. EDA (0.16 ml, 2.4 mmol) was added and the mixture was stirred at reflux for 
24 h. The mixture was worked up as it is described to give 0.10 g (53%) of beige powder; mp 
> 280 °C; 1H NMR (300 MHz, DMSO-d6) (δ/ppm): 11.96 (s, 1H, OH), 10.63 – 10.62 (m, 3H, 
NHamidine, OH), 10.38 (s, 1H, NHamide), 8.06 (d, J = 8.7 Hz, 2H, Harom), 7.99 (d, J = 8.8 Hz, 2H, 
Harom), 7.94 (d, J = 8.6 Hz, 1H, Harom), 6.45 – 6.41 (m, 2H, Harom), 3.99 (s, 4H, CH2); 
13C NMR 
(75 MHz, DMSO-d6) (δ/ppm): 167.4, 164.6, 163.4, 161.2, 144.6, 131.7, 130.1 (2C), 120.6 (2C), 
116.9, 108.7, 108.3, 103.3, 44.7 (2C). 
3,4,5-Trihydroxy-N-[4-(imidazolin-2-yl)phenyl]benzamide 17     
The compound was prepared following the general method. A suspension of 0.14 g (0.5 mmol) 
3,4,5-trihydroxy-N-(4-cyanophenyl)benzamide 10 in anhydrous ethanol (15 ml) was saturated 
with dry HCl gas and stirred for 10 days. The crude imidate was filtered off and suspended in 
absolute ethanol. EDA (0.05 ml, 0.8 mmol) was added and the mixture was stirred at reflux for 
24 h. The mixture was worked up as it is described to give 0.03 g (24%) of yellow powder; mp 
> 280 °C; 1H NMR (300 MHz, DMSO-d6) (δ/ppm): 10.50 (s, 2H, NHamidine), 10.38 (s, 1H, 
NHamide), 9.24 (s, 2H, OH), 9.01 (s, 1H, OH), 8.02 (d, J = 9.2 Hz, 2H, Harom), 7.98 (d, J = 9.2 
Hz, 2H, Harom), 6.99 (s, 2H, Harom), 3.98 (s, 4H, CH2); 
13C NMR (75 MHz, DMSO-d6) (δ/ppm): 
166.6, 164.8, 146.01, 145.8, 138.0, 130.0 (2C), 124.6, 120.0 (2C), 116.3, 107.9 (2C), 44.7 (2C). 
2-Hydroxy-N-[5(6)-amidino-1H-benzimidazol-2-yl]benzamide 30      
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The compound was prepared following the general method. A suspension of 0.14 g (0.5 mmol) 
2-hydroxy-N-[5(6)-cyano-1H-benzimidazol-2-yl]benzamide 26 in anhydrous ethanol (15 ml) 
was saturated with dry HCl gas and stirred for 9 days. The crude imidate was filtered off, 
suspended in absolute ethanol (10 ml) and dry NH3 was bubbled into the suspension. The 
mixture was worked up as it is described to give 0.04 g (58%) of light yellow powder; mp > 
280 °C; 1H NMR (600 MHz, DMSO-d6) (δ/ppm): 17.49 (brs, 1H, OH), 12.44 (brs, 1H, NHamide), 
9.08 (s, 2H, NHamidine), 8.53 (s, 2H, NHamidine), 7.87 – 7.80 (m, 2H, Harom), 7.50 (s, 1H, Harom), 
7.45 (d, J = 8.0 Hz, 1H, Harom), 7.15 (t, J = 7.5 Hz, 1H, Harom), 6.63 (d, J = 8.2 Hz, 1H, Harom), 
6.53 (t, J = 7.2 Hz, 1H, Harom); 
13C NMR (150 MHz, DMSO-d6) (δ/ppm): 170.6, 166.9 (2C), 
166.4, 132.8, 129.5 (2C), 120.6, 119.4, 119.1 (2C), 114.4. 
2-Hydroxy-4-methoxy -N-[5(6)-amidino-1H-benzimidazol-2-yl]benzamide 31     
The compound was prepared following the general method. A suspension of 0.08 g (0.3 mmol) 
27 in anhydrous ethanol (10 ml) was saturated with dry HCl gas and stirred for 9 days. The 
crude imidate was filtered off, suspended in absolute ethanol (10 ml) and dry NH3 was bubbled 
into the suspension. The mixture was worked up as it is described to give 0.05 g (57%) of light 
brown powder; mp 255–260°C; 1H NMR (300 MHz, DMSO-d6) (δ/ppm): 17.12 (brs, 1H, OH), 
12.23 (brs, 1H, NHbenzimidazole), 8.76 (brs, 4H, NHamidine), 7.83 (s, 1H, Harom), 7.70 (s, 1H, Harom), 
7.48 (s, 2H, Harom), 6.09 (s, 2H, Harom), 3.70 (s, 3H, CH3); 
13C NMR (150 MHz, DMSO-d6) 
(δ/ppm): 166.1, 165.5, 163.9, 163.1, 154.8, 132.9, 131.4, 130.5, 121.4, 121.1, 119.3, 118.4, 
101.2, 55.2. 
2-Hydroxy-N-(6-amidinobenzothiazol-2-yl)benzamide 32    
The compound was prepared following the general method. A suspension of 0.20 g (0.7 mmol) 
28 in anhydrous ethanol (15 ml) was saturated with dry HCl gas and stirred for 10 days. The 
crude imidate was filtered off, suspended in absolute ethanol (10 ml) and dry NH3 was bubbled 
into the suspension. The mixture was worked up as it is described to give 0.03 mg (12%) of 
beige powder; mp > 280 °C; 1H NMR (300 MHz, DMSO-d6) (δ/ppm): 15.75 (brs, 1H, OH), 
9.14 (brs, 2H, NHamidine), 8.63 (brs, 2H, NHamidine), 8.26 (d, J = 1.3 Hz, 1H, Harom), 7.88 (dd, J1 
= 7.7 Hz, J2 = 1.7 Hz, 1H, Harom), 7.73 – 7.62 (m, 2H, Harom), 7.25 (t, J = 8.5 Hz, 1H, Harom), 
6.83 – 6.69 (m, 2H, Harom); 
13C NMR (75 MHz, DMSO-d6) (δ/ppm): 171.3, 169.4, 165.8, 162.2, 
155.4, 133.6, 132.9, 129.8, 125.4, 122.0, 120.3, 119.9, 119.0, 117.5, 117.4. 
2-Hydroxy-4-methoxy-N-(6-amidinobenzothiazol-2-yl)benzamide 33  
The compound was prepared following the general method. A suspension of 0.08 g (0.2 mmol) 
2-hydroxy-4-methoxy-N-(6-cyanobenzothiazol-2-yl)benzamide 29 in anhydrous ethanol (10 
ml) was saturated with dry HCl gas and stirred for 9 days. The crude imidate was filtered off, 
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suspended in absolute ethanol (10 ml) and dry NH3 was bubbled into the suspension. The 
mixture was worked up as it is described to give 0.04 mg (40%) of white powder; mp > 280 °C; 
1H NMR (300 MHz, DMSO-d6) (δ/ppm): 13.02 (brs, 2H, OH, NHamide), 9.29 (brs, 2H, 
NHamidine), 8.99 (brs, 2H, NHamidine), 8.47 – 8.43 (m, 1H, Harom), 7.96 – 7.88 (m, 1H, Harom), 7.85 
– 7.75 (m, 2H, Harom), 6.52 (s, 2H, Harom), 3.80 (s, 3H, CH3); 
13C NMR (150 MHz, DMSO-d6) 
(δ/ppm): 165.5, 164.4, 160.6, 131.9, 129.6, 126.8, 126.0, 122.6, 122.3, 119.3, 109.5, 106.7, 
104.9, 102.8, 101.4, 55.4. 
2-Hydroxy-N-[5(6)-(imidazolinil-2-yl)-1H-benzimidazol-2-yl]benzamide 34   
The compound was prepared following the general method. A suspension of 0.14 g (0.5 mmol) 
2-hydroxy-N-[5(6)-cyano-1H-benzimidazol-2-yl]benzamide 26 in anhydrous methoxyethanol 
(15 ml) was saturated with dry HCl gas and stirred for 9 days. The crude imidate was filtered 
off and suspended in absolute ethanol (10 ml). EDA (0.05 ml, 0.8 mmol) was added and the 
mixture was stirred at reflux for 24 h. The mixture was worked up as it is described to give 0.05 
g (68%) of white powder; mp > 280 °C; 1H NMR (600 MHz, DMSO-d6) (δ/ppm): 17.36 (brs, 
1H, OH), 12.41 (brs, 1H, NHbenzimidazole), 9.63 (brs, 2H, NHamidine), 7.92 (s, 1H, Harom), 7.86 (dd, 
J1 = 7.7, J2 = 1.5 Hz, 1H, Harom), 7.57 (d, J = 8.3 Hz, 1H, Harom), 7.51 (d, J = 8.0 Hz, 1H, Harom), 
7.17 (t, J = 7.6 Hz, 1H, Harom), 6.65 (d, J = 8.2 Hz, 1H, Harom), 6.56 (t, J = 7.4 Hz, 1H, Harom), 
3.94 (s, 4H, CH2); 
13C NMR (75 MHz, DMSO-d6) (δ/ppm): 165.7, 134.7, 130.7, 123.6, 119.4, 
117.7 (2C), 116.4, 113.6, 44.8 (2C). 
2-Hydroxy-4-methoxy -N-[5(6)-(imidazolinil-2-yl)-1H-benzimidazol-2-yl]benzamide 35  
The compound was prepared following the general method. A suspension of  0.08 mg (0.02 
mmol) 2-hydroxy-4-methoxy-N-[5(6)-cyano-1H-benzimidazol-2-yl]benzamide 27 in 
anhydrous metoxyethanol (10 ml) was saturated with dry HCl gas and stirred for 9 days. The 
crude imidate was filtered off and suspended in absolute ethanol (10 ml). EDA (0.02 ml, 0.4 
mmol) was added and the mixture was stirred at reflux for 24 h. The mixture was worked up as 
it is described to give 0.02 g (38%) of white powder; mp > 280 °C; 1H NMR (300 MHz, DMSO-
d6) (δ/ppm): 10.02 (brs, 2H, NHamidine), 7.92 (s, 1H, Harom), 7.74 (d, J = 8.4 Hz, 1H, Harom), 7.59 
– 7.49 (m, 2H, Harom), 6.13 – 6.09 (m, 2H, Harom), 3.95 (s, 4H, CH2), 3.71 (s, 3H, CH3); 
13C 
NMR (75 MHz, DMSO-d6) (δ/ppm): 169.7, 166.5, 163.9, 155.8, 154.8, 133.7, 130.7, 125.6, 
121.9, 121.1, 119.0, 114.6, 113.4, 112.1, 102.4, 55.2, 45.0 (2C). 
2-Hydroxy-N-[6-(imidazolinil-2-yl)benzothiazol-2-yl]benzamide 36  
The compound was prepared following the general method. A suspension of 0.20 g (0.7 mmol) 
28 in anhydrous ethanol (15 ml) was saturated with dry HCl gas and stirred for 9 days. The 
crude imidate was filtered off and suspended in absolute ethanol (10 ml). EDA (0.08 ml, 1.2 
29 
 
mmol) was added and the mixture was stirred at reflux for 24 h. The mixture was worked up as 
it is described to give 0.08 g (56%) of beige powder; mp > 280 °C; 1H NMR (600 MHz, DMSO-
d6) (δ/ppm): 15.69 (brs, 1H, OH), 9.49 (brs, 2H, NHamidine), 8.37 (s, 1H, Harom), 7.90 (d, J = 6.9 
Hz, 1H, Harom), 7.82 (d, J = 8.0 Hz, 1H, Harom), 7.70 (d, J = 8.5 Hz, 1H, Harom), 7.28 (t, J = 6.7 
Hz, 1H, Harom), 6.80 – 6.76 (m, 2H, Harom), 3.99 (s, 4H, CH2); 
13C NMR (75 MHz, DMSO-d6) 
(δ/ppm): 171.2, 165.6, 161.8, 155.7, 133.7, 133.1, 129.9, 125.7, 122.3, 120.1, 119.4, 118.0, 
117.7, 117.5, 114.2, 44.7 (2C). 
2-Hydroxy-4-methoxy-N-[6-(imidazolinil-2-yl)benzothiazol-2-yl]benzamide 37   
The compound was prepared following the general method. A suspension of 0.08 g (0.2 mmol) 
2-hydroxy-4-methoxy-N-(6-cyanobenzothiazol-2-yl)benzamide 29 in anhydrous ethanol (10 
ml) was saturated with dry HCl gas and stirred for 9 days. The crude imidate was filtered off 
and suspended in absolute ethanol (10 ml). EDA (0.03 ml, 0.5 mmol) was added and the mixture 
was stirred at reflux for 24 h. The mixture was worked up as it is described to give 0.02 g (23%) 
of white powder; mp > 280 °C; 1H NMR (600 MHz, DMSO-d6) (δ/ppm): 16.21 (brs, 1H, OH), 
9.69 (brs, 2H, NHamidine), 8.33 (s, 1H, Harom), 7.81 – 7.77 (m, 2H, Harom), 7.66 (d, J = 8.4 Hz, 
1H, Harom), 6.33 (d, J = 8.7 Hz, 1H, Harom), 6.31 (s, 1H, Harom), 3.98 (s, 4H, CH2), 3.75 (s, 3H, 
CH3).  
2-Methoxy-N-(6-amidinobenzothiazol-2-yl)benzamide 40  
The compound was prepared following the general method. A suspension of 0.15 g (0.5 mmol) 
2-methoxy-N-(6-cyanobenzothiazol-2-yl)benzamide 23 in anhydrous ethanol (20 ml) was 
saturated with dry HCl gas and stirred for 9 days. The crude imidate was filtered off, suspended 
in absolute ethanol (10 ml) and dry NH3 was bubbled into the suspension. The mixture was 
worked up as it is described to give 0.14 g (81%) of white powder; mp 258–261°C; 1H NMR 
(300 MHz, DMSO-d6) (δ/ppm): 8.76 (brs, 4H, NHamidine), 8.22 (s, 1H, Harom), 7.70 (d, J = 7.7 
Hz, 1H, Harom), 7.58 – 7.53 (m, 2H, Harom), 7.32 (t, J = 7.1 Hz, 1H, Harom), 7.03 (d, J = 8.2 Hz, 
1H, Harom), 6.95 (t, J = 7.3 Hz, 1H, Harom), 3.79 (s, 3H, OCH3); 
13C NMR (75 MHz, DMSO-d6) 
(δ/ppm): 165.7, 157.4, 133.5, 130.0, 125.1, 121.7, 120.3, 118.3, 112.5, 56.0. 
 
 
2,4-Dimethoxy-N-(6-amidinobenzothiazol-2-yl)benzamide 41     
The compound was prepared following the general method. A suspension of 0.23 g (6.6 mmol) 
2,4-dimethoxy-N-(6-cyanobenzothiazol-2-yl)benzamide 24 in anhydrous methoxyethanol (20 
ml) was saturated with dry HCl gas and stirred for 27 days. The crude imidate was filtered off, 
suspended in absolute ethanol (15 ml) and dry NH3 was bubbled into the suspension. The 
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mixture was worked up as it is described to give 0.09 mg (33%) of white powder; mp 261–264 
°C; 1H NMR (600 MHz, DMSO-d6) (δ/ppm): 11.86 (s, 1H, NHamide), 8.58 (s, 1H, Harom), 7.88 
(d, J = 8.3 Hz, 1H, Harom), 7.85 – 7.83 (m, 2H, Harom), 6.75 (s, 1H, Harom), 6.72 (d, J = 8.5 Hz, 
1H, Harom), 3.99 (s, 3H, OCH3), 3.86 (s, 3H, OCH3); 
13C NMR (150 MHz, DMSO-d6) (δ/ppm): 
164.7, 163.9, 161.6, 159.6, 151.8, 132.8, 132.6, 129.5, 126.8, 121.1, 119.0, 112.5, 106.8, 105.5, 
99.0, 56.6, 55.8. 
3,4,5-Trimethoxy-N-(6-amidinobenzothiazol-2-yl)benzamide 42  
The compound was prepared following the general method. A suspension of 0.18 g (0.5 mmol) 
3,4,5-trimethoxy-N-(6-cyanobenzothiazol-2-yl)benzamide 25 in anhydrous methoxyethanol 
(20 ml) was saturated with dry HCl gas and stirred for 70 days. The crude imidate was filtered 
off, suspended in absolute ethanol (8 ml) and dry NH3 was bubbled into the suspension. The 
mixture was worked up as it is described to give 0.05 mg (26%) of white powder; mp > 280 °C; 
1H NMR (600 MHz, DMSO-d6) (δ/ppm): 8.55 (s, 1H, Harom.), 7.89 (s, 2H, Harom.), 7.53 (s, 2H, 
Harom.), 7.39 (s, 4H, NHamidine), 3.87 (s, 6H, OCH3), 3.74 (s, 3H, OCH3). 
2-Methoxy-N-[6-(imidazolinil-2-yl)benzothiazol-2-yl]benzamide 45  
The compound was prepared following the general method. A suspension of 0.15 g (0.5 mmol) 
2-hydroxy-4-methoxy-N-(6-cyanobenzothiazol-2-yl)benzamide 29 in ethanol (20 ml) was 
saturated with dry HCl gas and stirred for 9 days. The crude imidate was filtered off and 
suspended in absolute ethanol (10 ml). EDA (0.11 ml, 3.4 mmol) was added and the mixture 
was stirred at reflux for 24 h. The mixture was worked up as it is described to give 0.15 g (81%) 
of beige powder; mp > 280 °C; 1H NMR (600 MHz, DMSO-d6) (δ/ppm): 10.84 (brs, 2H, 
NHamidine), 8.76 (s, 1H, Harom), 8.09 (d, J = 8.5 Hz, 1H, Harom), 7.96 (d, J = 8.5 Hz, 1H, Harom), 
7.77 (d, J = 6.3 Hz, 1H, Harom), 7.60 (t, J = 7.2 Hz, 1H, Harom), 7.25 (d, J = 8.4 Hz, 1H, Harom), 
7.12 (t, J = 7.5 Hz, 1H, Harom), 4.00 (s, 4H, CH2), 3.96 (s, 3H, OCH3); 
13C NMR (150 MHz, 
DMSO-d6) (δ/ppm): 165.8, 165.4, 162.1, 158.0, 153.4, 134.5, 132.7, 130.9, 127.0, 123.7, 121.7, 
121.4, 121.3, 117.6, 113.0, 56.8, 44.9 (2C). 
2,4-Dimethoxy-N-[6-(imidazolinil-2-yl)benzothiazol-2-yl]benzamide 46       
The compound was prepared following the general method. A suspension of 0.23 g (6.6 mmol) 
2-hydroxy-4-methoxy-N-(6-cyanobenzothiazol-2-yl)benzamide 29 in anhydrous 
methoxyethanol (20 ml) was saturated with dry HCl gas and stirred for 27 days. The crude 
imidate was filtered off and suspended in absolute ethanol (10 ml). EDA (0.06 ml, 0.9 mmol) 
was added and the mixture was stirred at reflux for 24 h. The mixture was worked up as it is 
described to give 0.09 g (34%) of light yellow powder; mp 261–264 °C; 1H NMR (600 MHz, 
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DMSO-d6) (δ/ppm): 10.64 (brs, 2H, NHamidine), 8.58 (d, J = 1.3 Hz, 1H, Harom), 7.88 (d, J = 8.4 
Hz, 1H, Harom), 7.85 – 7.82 (m, 2H, Harom), 6.75 (d, J = 2.1 Hz, 1H, Harom), 6.71 (dd, J1 = 8.7, 
J2 = 2.2 Hz, 1H, Harom), 3.99 (s, 3H, OCH3), 3.86 (s, 3H, OCH3); 
13C NMR (150 MHz, DMSO-
d6) (δ/ppm): 164.7, 164.0, 161.6, 159.5, 151.8, 132.8, 129.6, 126.9, 121.1, 119.0, 112.5, 106.7, 
105.5, 98.9, 56.6, 55.8. 
3,4,5-Trimethoxy-N-[6-(imidazolin-2-yl)benzothiazol-2-yl]benzamide 47 
The compound was prepared following the general method. A suspension of 0.18 g (0.5 mmol) 
3,4,5-trimethoxy-N-(6-cyanobenzothiazol-2-yl)benzamide 25 in anhydrous methoxyethanol 
(20 ml) was saturated with dry HCl gas and stirred for 70 days. The crude imidate was filtered 
off and suspended in absolute ethanol (8 ml). EDA (0.05 ml, 1.7 mmol) was added and the 
mixture was stirred at reflux for 24 h. The mixture was worked up as it is described to give 0.04 
g (45%) of light yellow powder; mp > 280 °C; 1H NMR (600 MHz, DMSO-d6) (δ/ppm): 13.32 
(brs, 1H, NHamide), 10.79 (s, 2H, NHamidine), 8.79 (s, 1H, Harom), 8.14 (d, J = 8.2 Hz, 1H, Harom), 
8.01 (d, J = 8.6 Hz, 1H, Harom), 7.57 (s, 2H, Harom), 4.04 (s, 3H, OCH3), 3.91 (s, 4H, CH2), 3.11 
(s, 6H, OCH3); 
13C NMR (150 MHz, DMSO-d6) (δ/ppm): 165.7, 153.3, 142.0, 127.7, 124.8, 
124.5, 106.5 (2C), 60.6, 56.6 (2C), 43.2 (2C). 
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